Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ADJUVANT
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
- NCT01405079 ↗
- Unknown
- Guangdong Association of Clinical Trials
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on ADJUVANT yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ADJUVANT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 21 posts on X | |
| 3 podcast episodes | |
| 1 video on X |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR Mutation
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Gefitinib; Vinorelbine+Cisplatin
- Arms
- Gefitinib · Experimental
- Vinorelbine+Cisplatin · Active comparator
- Enrollment
- 222
- Primary outcomes
- Disease free survival
- Sponsor
- Guangdong Association of Clinical Trials with Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Jilin Provincial Tumor Hospital, Liaoning Cancer Hospital & Institute, First Hospital of China Medical University, Chinese PLA General Hospital, Peking Union Medical College Hospital, Peking University People's Hospital, Beijing Chest Hospital, 309th Hospital of Chinese People's Liberation Army, Peking University Cancer Hospital & Institute, Peking University First Hospital, Tianjin Medical University Cancer Institute and Hospital, The Affiliated Hospital of Qingdao University, Jiangsu Cancer Institute & Hospital, The First Affiliated Hospital of Soochow University, Fudan University, Shanghai Pulmonary Hospital, Shanghai, China, Zhejiang Cancer Hospital, Zhejiang University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tongji Hospital, West China Hospital, Tang-Du Hospital
- Start
- Sep 19, 2011
- Primary completion
- Mar 2017
- Results posted
- No
- Registry record
- NCT01405079 · updated Feb 18, 2020
Publications
linked from the registry- Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2011 Mar;6(3):569-75. doi: 10.1097/JTO.0b013e318202bffe. PubMed 21150674
- Occhipinti M, Imbimbo M, Ferrara R, Simeon V, Fiscon G, Marchal C, Skoetz N, Viscardi G. Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2. PubMed 40421698
- Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):713-722. doi: 10.1200/JCO.20.01820. Epub 2020 Dec 17. PubMed 33332190
- Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. PubMed 29174310